KPT330 Enhances CRISPR-Cas9 Specificity via mRNA Nuclear Exp
2026-07-31
This study demonstrates that KPT330, an FDA-approved SINE compound, improves the specificity of CRISPR-Cas9 genome and base editing by selectively inhibiting the nuclear export of Cas9 mRNA. The findings highlight a novel, indirect mechanism for modulating genome editing fidelity in mammalian cells and provide a basis for integrating small-molecule control with mRNA engineering approaches.
Spleen-Targeted Neoantigen mRNA Vaccine Drives TLS Formation
2026-07-30
Lin et al. introduce a spleen-targeted mRNA vaccine that elicits potent antitumor immunity in hepatocellular carcinoma by promoting ISG15+ CD8+ T cell activation and tertiary lymphoid structure (TLS) formation. This work reveals a novel mechanism of organ-targeted mRNA immunotherapy and provides a foundation for improving cancer vaccine strategies in otherwise immune-refractory tumors.
Cy3-dCTP: Precision Fluorescent Labeling for Advanced DNA As
2026-07-30
Cyanine 3-dCTP empowers streamlined, high-sensitivity direct enzymatic labeling of DNA and cDNA, supporting multicolor detection and robust probe generation. Its superior incorporation efficiency and compatibility with modern syntheses, including highly ordered DNA frameworks, make it a pivotal tool for genomics, diagnostics, and synthetic biology.
Remdesivir (GS-5734): Applied Workflows for Antiviral Resear
2026-07-29
Leverage Remdesivir (GS-5734) for reproducible, high-sensitivity antiviral assays targeting RNA viruses. This article delivers stepwise protocols, actionable troubleshooting, and strategic insights to advance coronavirus and Ebola virus research with confidence.
In Situ CAR Macrophage Programming via mRNA-LNP for Tumor Im
2026-07-29
This study introduces a macrophage-targeted mRNA lipid nanoparticle (mRNA-LNP) system for in situ programming of chimeric antigen receptor macrophages (CAR-Ms) to treat peritoneal metastasis of solid tumors. By systematically evaluating multiple CAR constructs and revealing their impact on the tumor immune microenvironment, the work advances mechanistic understanding and experimental strategies in oncology immunotherapy.
UBR1 and UBR2: Central Sensors of ER Stress in Mammalian PQC
2026-07-28
The study identifies UBR1 and UBR2 as pivotal E3 ligases acting as ER stress sensors that regulate protein quality control in mammalian cells. This work clarifies their stabilization during ER stress, adds mechanistic depth to the N-degron pathway’s role in ER-associated degradation, and informs design of targeted proteasome pathway research.
T7 RNA Polymerase: Precision RNA Synthesis for Advanced mRNA
2026-07-28
Explore the scientific foundations and emerging applications of T7 RNA Polymerase, a recombinant enzyme expressed in E. coli, as a cornerstone for precise in vitro transcription. This article uniquely connects molecular mechanisms with translational mRNA vaccine design, providing actionable insights not found elsewhere.
Machine Learning-Guided Design of LNPs for mRNA Vaccines
2026-07-27
This study introduces a machine learning approach to predict and optimize lipid nanoparticle (LNP) formulations for mRNA vaccine delivery, surpassing traditional empirical methods in efficiency and insight. The model identifies critical ionizable lipid substructures—such as those found in SM-102 and MC3—and demonstrates predictive validity in experimental settings, accelerating rational design of mRNA vaccine delivery systems.
Patient-Derived Gastric Cancer Assembloids Reveal Tumor-Stro
2026-07-27
This study introduces a novel patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations. The approach closely mimics primary tumor heterogeneity, enabling investigation of drug resistance and personalized therapy optimization.
Morphology of RNA-CART Nanoparticles: Implications for mRNA
2026-07-26
This article reviews the structural and mechanistic insights from Hurst et al. on how amphiphilic Charge-Altering Releasable Transporters (CARTs) self-assemble with RNA to form bicontinuous nanoparticles. Their findings clarify how specific polymer and RNA features determine vector morphology, informing the rational design of next-generation mRNA delivery systems.
Primary Antibody Dilution Buffer: Precision in CNS Lymphoma
2026-07-25
Unlock reproducible, high-sensitivity immunoassays in even the most challenging CNS lymphoma tissues. APExBIO's Primary Antibody Dilution Buffer delivers unmatched specificity and robust signal clarity through optimized antibody penetration and non-specific binding reduction, setting a new standard for research in hypoxic, metabolically unique tumor environments.
Antiarrhythmic Drugs and KCa2 Channel Modulation in AF Resea
2026-07-24
This study systematically investigates whether clinically recommended antiarrhythmic agents—including dronedarone—directly inhibit small conductance calcium-activated potassium (KCa2.X) channels, a proposed atrial-selective target for atrial fibrillation (AF) management. The findings reveal that most current drugs exert negligible inhibition of these channels at therapeutic concentrations, refining the mechanistic understanding of AF pharmacotherapy and guiding future research priorities.
MLN4924: NEDD8-Activating Enzyme Inhibitor for Cancer Models
2026-07-24
MLN4924 sets a new benchmark in dissecting neddylation pathway inhibition for targeted cancer biology research. This guide delivers actionable protocols, workflow enhancements, and troubleshooting tips grounded in the latest data, empowering researchers to unlock the full translational potential of MLN4924.
Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Relia
2026-07-23
This article delivers scenario-driven guidance for using Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) (SKU K1010) in critical protein assays. By addressing real-world challenges in protein extraction, phosphorylation analysis, and assay compatibility, we demonstrate how APExBIO's EDTA-free formulation preserves sample integrity and supports reproducible, high-sensitivity data.
Advancing In Vitro Cancer Drug Evaluation: Distinguishing Gr
2026-07-23
Schwartz's dissertation introduces a refined framework for in vitro assessment of anti-cancer agents by separating relative from fractional viability, enabling clearer interpretation of drug-induced proliferation arrest versus cell death. This methodological advance enhances the predictive power and sensitivity of preclinical drug screening, especially for apoptosis inducers.
458 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page